Andrea De Giglio

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 19

Top Topics

Tyrosine Kinase

Clinical Evaluation

Brain Metastases

Top Venues

Future oncology (London, England)

Diagnostics (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Mirta Mosca, Maria Concetta Nigro, Rachele Pagani, Andrea De Giglio, Alessandro Di Federico
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond. Biomolecules 13 (12) (2023)
Mirta Mosca, Nicole Conci, Alessandro Di Federico, Valentina Tateo, Valentina Favorito, Arianna Zappi, Francesco Gelsomino, Andrea De Giglio
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. JCO precision oncology 7 (2023)
Mirta Mosca, Maria Concetta Nigro, Rachele Pagani, Andrea De Giglio, Alessandro Di Federico
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond. Biomolecules 13 (12) (2023)
Laura Fabbri, Alessandro Di Federico, Martina Astore, Virginia Marchiori, Agnese Rejtano, Renata Seminerio, Francesco Gelsomino, Andrea De Giglio
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC). Diagnostics (Basel, Switzerland) 14 (1) (2023)
Laura Fabbri, Alessandro Di Federico, Martina Astore, Virginia Marchiori, Agnese Rejtano, Renata Seminerio, Francesco Gelsomino, Andrea De Giglio
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC). Diagnostics (Basel, Switzerland) 14 (1) (2023)
Mirta Mosca, Maria Concetta Nigro, Rachele Pagani, Andrea De Giglio, Alessandro Di Federico
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond. Biomolecules 13 (12) (2023)
Andrea De Giglio, Elisa Tassinari, Arianna Zappi, Alessandro Di Federico, Barbara Lenzi, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Marco Maltoni, Andrea Ardizzoni
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy. Cancers 14 (23) (2022)
Andrea De Giglio, Elisa Tassinari, Arianna Zappi, Alessandro Di Federico, Barbara Lenzi, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Marco Maltoni, Andrea Ardizzoni
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy. Cancers 14 (23) (2022)
Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers 14 (10) (2022)
Andrea De Giglio, Marta Aprile, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Andrea Ardizzoni
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC). International journal of molecular sciences 23 (18) (2022)
Andrea De Giglio, Elisa Tassinari, Arianna Zappi, Alessandro Di Federico, Barbara Lenzi, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Marco Maltoni, Andrea Ardizzoni
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy. Cancers 14 (23) (2022)
Andrea De Giglio, Valentina Orlando, Elisa Andrini, Biagio Ricciuti, Giuseppe Lamberti, Rita Chiari
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities. Tumori (2022)
Andrea De Giglio, Chiara Deiana, Alessandro Di Federico
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients. Journal of cancer research and clinical oncology (2022)
Elisa Andrini, Alessandro Di Federico, Monia Sisi, Matteo Rosellini, Arianna Palladini, Giuseppe Lamberti, Andrea De Giglio, Francesco Gelsomino
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. Immunotherapy 14 (16) (2022)
Alessandro Di Federico, Andrea De Giglio, Francesco Gelsomino, Dario de Biase, Francesca Giunchi, Arianna Palladini, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes. Cancers 14 (14) (2022)
Andrea De Giglio, Elisa Tassinari, Arianna Zappi, Alessandro Di Federico, Barbara Lenzi, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Marco Maltoni, Andrea Ardizzoni
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy. Cancers 14 (23) (2022)
Valentina Tateo, Lisa Manuzzi, Claudia Parisi, Andrea De Giglio, Davide Campana, Maria Abbondanza Pantaleo, Giuseppe Lamberti
An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. Pharmaceuticals (Basel, Switzerland) 14 (4) (2021)
Alessandro Di Federico, Andrea De Giglio, Giacomo Nuvola, Chiara Deiana, Nicole Conci, Francesco Gelsomino, Andrea Ardizzoni
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis. Future oncology (London, England) 17 (32) (2021)
Andrea De Giglio, Giacomo Nuvola, Capucine Baldini
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: age, Eastern Cooperative Organization performance status 2, steroids and antibiotics. Future oncology (London, England) 16 (23) (2020)